NEJM 10 1 2026 Obexelimab for the Treatment of IgG4-Related Disease
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
NEJM 10 1 2026 Obexelimab for the Treatment of IgG4-Related Disease
-
ナレーター：
-
著者：
A recent phase 3 clinical trial investigated obexelimab, a novel monoclonal antibody that suppresses B-cell function without destroying the cells, as a potential therapy for IgG4-related disease. Standard treatments typically rely on glucocorticoids, which often cause significant toxicity and frequently lead to relapses once stopped. To test the medication, 194 patients were randomly assigned to receive either weekly subcutaneous injections of obexelimab or a placebo while systematically tapering off steroids. The findings demonstrated that obexelimabsubstantially reduced the likelihood of disease flare-ups, prolonged the duration of remission, and lowered the overall requirement for rescue steroid medications compared to the placebo group. Ultimately, the study indicates that obexelimab offers a safer and more effective alternative for managing this chronic inflammatory condition while minimizing harmful steroid exposure.